InStem And Curie Institute Scientists Develop Molecular Sensor To Detect Cancer Drugs

Mumbai : The Institute for Stem Cell Science and Regenerative Medicine (InStem), Bengaluru in collaboration with Curie Institute, Orsay, France, has developed a molecular sensor, which can identify cancer drugs by detecting how such chemicals modify microtubules inside living cells.

Microtubules are part of the cytoskeleton, a structural network within the cell’s cytoplasm, and they alter in response to several chemicals.

“Understanding tubulin modifications have remained a challenge till date because of unavailability of tools that can mark them in living cells. Both the researchers have overcome this shortcoming and developed the first tubulin nanobody – or sensor to study the dynamics of microtubule modifications in living cells and use this for identification of new cancer therapeutic drugs”, said the statement issued by the Department of Science and Technology (DST).

The researchers from Bengaluru and Orsay devised a method to design synthetic proteins, known as nanobodies, which can bind specifically to modified microtubules. These nanobodies are similar to antibodies made in our body as a defense mechanism against pathogens. However, unlike antibodies, the nanobodies are smaller in size and easily amenable for protein engineering. The nanobody was then coupled with a fluorescent molecule to serve as a detection tool, called sensor. They developed and validated a live cell sensor against a unique microtubule modification called tyrosinated form of microtubules that is already known to be important for cell division and intracellular organization.

The tyrosination sensor is the first tubulin nanobody – or sensor – that can be used to study the dynamics of microtubule modifications in living cells. Indo-French Centre for the Promotion of Advanced Research (IFCPAR/CEFIPRA) researchers has shown the application of this sensor in studying the effect of small-molecule compounds that target microtubules. These chemicals are frequently used as anti-cancer drugs. Thus, the tyrosination sensor will facilitate studying microtubule functions for many researchers and will aid identifying new drugs of therapeutic value.

  • Related Posts

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    New Delhi: The entry of semaglutide generics in India is ‘stimulating’ market growth and providing a favourable push to Eli Lilly’s blockbuster brand Mounjaro (tirzepatide), said Patrik Jonsson, Executive Vice…

    Pak-made illegal cosmetics recovered from Itwari shop

    Nagpur: Maharashtra Food and Drug Administration (FDA), Nagpur Division, raided a cosmetics firm in Itwari market and seized Pakistan-origin beauty products suspected to have harmful mercury and steroids last week. The…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Pak-made illegal cosmetics recovered from Itwari shop

    Pak-made illegal cosmetics recovered from Itwari shop

    Licences of 20 medical stores suspended after inspections

    Licences of 20 medical stores suspended after inspections

    Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

    Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    HP accounts for 47 inferior drugs in March alert

    HP accounts for 47 inferior drugs in March alert